Deciphering the Self-antigen Specific T Cell Signature of Autoimmune Liver Diseases

Nantes University Hospital220 enrolled

Overview

The study aims to establish the molecular signature of autoimmune self-antigen-specific T cells in AutoImmune Liver Disease (AILD)

Study Type

OBSERVATIONAL

Enrollment

220

Conditions

Autoimmune Hepatitis Primary Biliary Cholangitis (PBC)Autoimmune Liver Disease Primary Sclerosing Cholangitis (PSC)

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * Patient informed consent * AIH with no previous treatment whose diagnosis is validated by at least 2 of the following criteria: * ALT\>2N or IgG\>1.1N * Presence of autoantibodies : ANA (antinuclear), ML (anti-smooth muscle), SLA (anti-soluble liver antigen), LKM1 (anti-endoplasmic reticulum), LC1 (anti-liver cytosol) * Presence of interface hepatitis on biopsy Exclusion Criteria: * HIV positive * HBV infection Positive * HCV serology positive and PCR positive

Locations (1)

Nantes University Hospital

Nantes, France

Outcomes

Primary Outcomes

Establish the molecular signature of autoimmune self-antigen-specific T cells in AILD

Time frame: 4 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.